Verastem Dirección

Dirección controles de criterios 0/4

El CEO de Verastem's es Dan Paterson , nombrado en Jun 2019, tiene una permanencia de 4.83 años. compensación anual total es $3.63M, compuesta por 15% salario y 85% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $258.35K. La antigüedad media del equipo directivo y de la junta directiva es de 4 años y 2.6 años, respectivamente.

Información clave

Dan Paterson

Chief Executive Officer (CEO)

US$3.6m

Compensación total

Porcentaje del salario del CEO	15.0%
Permanencia del CEO	4.9yrs
Participación del CEO	0.2%
Permanencia media de la dirección	1.2yrs
Promedio de permanencia en la Junta Directiva	2.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dan Paterson en comparación con los beneficios de Verastem?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$4m	US$545k	-US$87m
Sep 30 2023	n/a	n/a	-US$77m
Jun 30 2023	n/a	n/a	-US$75m
Mar 31 2023	n/a	n/a	-US$73m
Dec 31 2022	US$698k	US$470k	-US$74m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$78m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$2m	US$460k	-US$71m
Sep 30 2021	n/a	n/a	-US$75m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$45m
Dec 31 2020	US$2m	US$467k	-US$68m
Sep 30 2020	n/a	n/a	-US$87m
Jun 30 2020	n/a	n/a	-US$130m
Mar 31 2020	n/a	n/a	-US$149m
Dec 31 2019	US$2m	US$445k	-US$149m

Compensación vs. Mercado: La compensación total de Dan($USD3.63M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD759.95K).

Compensación vs. Ingresos: La compensación de Dan ha aumentado mientras la empresa no es rentable.

CEO

Dan Paterson (62 yo)

4.9yrs

Permanencia

US$3,626,857

Compensación

Mr. Daniel W. Paterson, also known as Dan, serves as Chief Executive Officer Verastem, Inc. since August 1, 2023 and is its President of Verastem, Inc. since June 2019. He is Director of Verastem, Inc. sin...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel Paterson	President	4.9yrs	US$3.63m	0.17% $ 477.9k
Daniel Calkins	CFO and Principal Accounting & Financial Officer	1.6yrs	US$622.56k	0.024% $ 66.5k
Richard Aldrich	Founder and Consultant	9.7yrs	US$114.77k	sin datos
Robert Weinberg	Co-Founder & Chair of Scientific Advisory Board	no data	sin datos	sin datos
Piyush Gupta	Co-Founder	no data	sin datos	sin datos
Michelle Dipp	Co-Founder	no data	sin datos	sin datos
Jonathan Pachter	Chief Scientific Officer	8.1yrs	US$319.51k	sin datos
Nate Sanburn	Senior Vice President of Corporate Development & External Engagement	less than a year	sin datos	sin datos
Cathy Carew	Chief Organizational Effectiveness Officer	no data	sin datos	sin datos
Michael Crowther	Chief Commercial & Business Strategy Officer	less than a year	sin datos	sin datos
Colleen Mockbee	Global Head of Regulatory Affairs & Development	less than a year	sin datos	sin datos
John Hayslip	Chief Medical Officer	less than a year	sin datos	sin datos

1.2yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0LOV no se considera experimentado ( 1.1 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel Paterson	President	less than a year	US$3.63m	0.17% $ 477.9k
Robert Weinberg	Co-Founder & Chair of Scientific Advisory Board	no data	sin datos	sin datos
Mario Sznol	Member of Scientific Advisory Board	no data	sin datos	sin datos
Michael Kauffman	Lead Independent Director	11.5yrs	US$124.29k	0.0022% $ 6.0k
Paul A. Bunn	Independent Director	2.9yrs	US$74.29k	0% $ 0
Eric Rowinsky	Independent Director	7yrs	US$89.29k	0% $ 0
John Johnson	Independent Director	4.1yrs	US$81.29k	0% $ 0
Robert Gagnon	Director	1.4yrs	US$64.29k	0.083% $ 228.0k
Channing Der	Member of Scientific Advisory Board	2.2yrs	sin datos	sin datos
Brian Stuglik	Director	6.7yrs	US$2.30m	0.29% $ 798.2k
Anil Kapur	Independent Director	1.6yrs	US$81.75k	0% $ 0
Michelle Robertson	Independent Director	2.5yrs	US$84.29k	0% $ 0

2.7yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de 0LOV no se considera experimentada (2.6 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Verastem Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Announces Executive Appointments

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Recent updates

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Launch of the New Healthcare Professional Component

Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million.

Verastem Oncology Announces Executive Appointments

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $85.018462 million.

Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Less than half of directors are independent

Verastem, Inc. announced that it expects to receive $59.995963 million in funding from BVF Partners L.P.

Verastem, Inc. announced that it expects to receive $60 million in funding

Verastem Oncology Appoints Rob Gagnon to the Board of Directors

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021)

Verastem Oncology Appoints Anil Kapur to Board of Directors

Verastem Oncology Announces RAMP VS-6766 Clinical Trials

Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021)

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 2000 Dynamic Index

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer

First quarter 2022 earnings released: US$0.091 loss per share (vs US$0.088 loss in 1Q 2021)

Less than half of directors are independent

Verastem, Inc., Annual General Meeting, May 12, 2022

Less than half of directors are independent

Full year 2021 earnings released: US$0.41 loss per share (vs US$0.44 loss in FY 2020)

Verastem, Inc. Announces Management Changes

CEO & Director recently sold US$53k worth of stock

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020)

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.098 loss per share (vs US$0.14 loss in 2Q 2020)

Forecast to breakeven in 2023

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 3000E Value Index

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

First quarter 2021 earnings released: US$0.088 loss per share (vs US$0.35 loss in 1Q 2020)

Verastem, Inc. Reports Updated Data from the LGSOC Cohort of the Ongoing, Investigator-Sponsored Phase 1/2 Frame Study Evaluating Vs-6766 in Combination with Defactinib in Patients with Recurrent LGSOC

Full year 2020 earnings released: US$0.44 loss per share (vs US$2.00 loss in FY 2019)

Verastem, Inc. Appoints Frank Neumann as Chief Medical Officer

Verastem, Inc. Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Secura Bio, Inc. completed the acquisition of Global Commercial and Development Rights of COPIKTRA from Verastem, Inc. (NasdaqGM:VSTM).

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad